From August 2021 to December 2021 my team and I worked as graduate student consultants for LabCorp, a biotechnology company that specializes in drug development and companion diagnostics for rare diseases and cancers. During this time, we focused on advancing efforts in biomarker discovery and drug development for the immune oncology and rare disease markets. I led a six-member team consisting of myself, Rachel Brunjes, Sophie Lindem, Logan Miller, Emory New, and Miguel Sanchez.
From August 2021 to September 2021, my team and I worked as graduate student consultants for the Comparative Medicine Institute at North Carolina State University. During this time, we specifically examined potential applications of CRISPR/Cas to viral disease diagnostics. I led a six-member team consisting of myself, Rachel Brunjes, Sophie Lindem, Logan Miller, Emory New, and Miguel Sanchez.
From February to May 2021, I served as one of five graduate student consultants for Biotalys, a biological crop protection company. I worked alongside team members Mila Parker (team lead), Billy Marx, Logan Miller, and Dilán Rivera.
From August to November 2020, I served as one of five graduate student consultants for North Carolina State University's Office of Research Commercialization. I worked alongside team members Mila Parker (team lead), Billy Marx, Logan Miller, and Dilán Rivera.
From January to February 2021, I served as one of five graduate student consultants for Syngenta, a seed and agrochemical company. I worked alongside team members Olivia Helvey (team lead), Jordan Bischoff, Allison Eble, and Daniel Onuoha.
From August to September 2020, I served as one of five graduate student consultants for the Comparative Medicine Institute (CMI) at North Carolina State University. I worked alongside team members Olivia Helvey (team lead), Jordan Bischoff, Allison Eble, and Daniel Onuoha.